login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
All US stocks
All Canadian stocks
All European stocks
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
LIGAND PHARMACEUTICALS (LGND) Stock News
NASDAQ:LGND -
US53220K5048
-
Common Stock
161.71
USD
+1.75 (+1.09%)
Last: 8/29/2025, 8:00:02 PM
161.71
USD
0 (0%)
After Hours:
8/29/2025, 8:00:02 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
LGND Latest News, Press Relases and Analysis
All
Press Releases
11 days ago - By: Ligand Pharmaceuticals
Ligand to Participate in September Investor Conferences
16 days ago - By: Ligand Pharmaceuticals
Ligand Announces Closing of Convertible Senior Notes Offering
19 days ago - By: Ligand Pharmaceuticals
Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering
19 days ago - By: Ligand Pharmaceuticals
Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030
23 days ago - By: The Motley Fool
Ligand (LGND) Q2 Revenue Jumps 15%
23 days ago - By: Benzinga
- Mentions:
GSAT
PGY
ADV
REAL
...
Earnings Scheduled For August 7, 2025
2 months ago - By: Ligand Pharmaceuticals
Ligand Partner Pelthos Therapeutics Launches ZELSUVMIâ„¢
23 days ago - By: Ligand Pharmaceuticals
Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance
a month ago - By: Orchestra BioMed Holdings, Inc.
- Mentions:
OBIO
MDT
Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed
a month ago - By: Ligand Pharmaceuticals
Ligand to Report Second Quarter 2025 Financial Results on August 7, 2025
2 months ago - By: Benzinga
- Mentions:
CHRO
PTHS
Pelthos Therapeutics Launches First At-Home Prescription Gel For Highly Contagious Skin Disease
4 months ago - By: Ligand Pharmaceuticals
Ligand Reports First Quarter 2025 Financial Results
4 months ago - By: Ligand Pharmaceuticals
Ligand to Participate in May Investor Conferences
2 months ago - By: Ligand Pharmaceuticals
Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics
3 months ago - By: Ligand Pharmaceuticals
Ligand Announces 2025 Investor Day in New York City
4 months ago - By: Ligand Pharmaceuticals
Ligand to Report First Quarter 2025 Financial Results on May 8, 2025
6 months ago - By: Ligand Pharmaceuticals
Ligand Reports Fourth Quarter and Full Year 2024 Financial Results
5 months ago - By: Ligand Pharmaceuticals
Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics
5 months ago - By: Yahoo Finance
- Mentions:
CHRO
NVDA
AAPL
EXCLUSIVE: Ligand Subsidiary Pelthos Therapeutics To Combine with Channel Therapeutics Creating Pain Medicines Focused Entity
7 months ago - By: Ligand Pharmaceuticals Incorporated
Ligand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
7 months ago - By: Ligand Pharmaceuticals Incorporated
Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
8 months ago - By: Investor's Business Daily
- Mentions:
MRNA
ALNY
EXEL
CORT
...
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
9 months ago - By: Ligand Pharmaceuticals Incorporated
Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance
9 months ago - By: Investor's Business Daily
- Mentions:
ACLX
GILD
JNJ
Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.
Please enable JavaScript to continue using this application.